Brief
Hutchinson Center, UW join NCI's ovarian-cancer clinical trial The Hutchinson Center joins nine other research institutions in a National Cancer Institute (NCI)-led clinical trial designed to build a repository of blood samples in order to develop an accurate means of detecting early reoccurrences of ovarian cancer. Researchers will collect a series of blood samples from women with advanced-stage ovarian cancer who show no signs of cancer after completing their first program of chemotherapy for ovarian cancer.
New biomarkers neededCA-125 (a test for a protein that is detectable in 80 percent of advanced stage patients with epithelial ovarian cancer) is currently the only approved test to see if ovarian cancer has returned, but it is not able to reliably diagnose women who have no signs of ovarian cancer. The scientists' long-term goal is to make a test that can predict the presence of early stage ovarian cancer using new technology that examines blood proteins.
Advanced-stage ovarian cancer has a high likelihood of returning within three years of initial treatment even when there are no signs of cancer being present. Current tests, such as CA-125 and transvaginal ultrasound, do not have good ability to predict whether cancer will return or not or for finding it in the first place. New bio-markers, such as those found in blood, are urgently needed.
The trial will enroll 400 women over 24 months. Researchers are looking for women who have advanced-stage ovarian cancer, have completed their initial chemotherapy within nine weeks of starting this trial, and show no evidence of cancer following completion of their first treatment program for which they received drugs such as carboplatin or cisplatin with paclitaxel, or docetaxel. The women will have a physical exam and routine laboratory tests performed every three months and a CT scan of the abdomen and pelvis (plus chest if indicated) every six months. Research samples will be frozen to create a repository for analysis of blood proteins. The study will also compare the blood protein test that is developed with CA-125 to see if it is better at predicting return of cancer than CA-125. Additional blood samples will be stored to create a repository so that other promising blood tests for ovarian cancer may be studied.
A pilot study launched in 2000 enhanced understanding of the complexities of protein analysis and reinforced the importance of collecting and analyzing a large number of blood samples and their protein patterns, said study leaders, who seek to create the best, most accurate, validated tests that give patients a high level of confidence in the results.
Ovarian cancer accounts for approximately four percent of all women's cancers and is the fourth leading cause of cancer-related death among women in the United States, with close to 16,000 women expected to die of the disease in 2005.
Enrollment of participantsThe first site opening for this trial is at NCI's clinical facility on the National Institutes of Health's campus in Bethesda, Md. The Hutchinson Center, University of Washington and other trial sites will begin enrolling patients later in 2005 or in 2006. The other participating institutions include: Cedars Sinai Medical Center, Los Angeles, Calif.; University of Alabama at Birmingham; Duke University Medical Center, Durham, N.C.; Fox Chase Cancer Center, Philadelphia, Pa.; University of Texas MD Anderson Cancer Center, Houston, Texas; Massachusetts General Hospital, Boston, Mass.; Northwestern Memorial Hospital, Chicago, Ill.; Evanston Northwestern University Hospital, Evanston, Ill.; New York University School of Medicine, New York, N.Y.
